Flagship Pioneering’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-7,932,624
| Closed | -$31.1M | – | 9 |
|
|
2023
Q3 | $31.1M | Buy |
7,932,624
+5,411,255
| +215% | +$36.9M | 2.26% | 7 |
|
|
2023
Q2 | $8.19M | Buy |
2,521,369
+3
| +0% | +$9 | 0.37% | 8 |
|
|
2023
Q1 | $9.11M | Hold |
2,521,366
| – | – | 0.35% | 9 |
|
|
2022
Q4 | $81.2M | Hold |
2,521,366
| – | – | 2.59% | 5 |
|
|
2022
Q3 | $105M | Hold |
2,521,366
| – | – | 4.44% | 6 |
|
|
2022
Q2 | $106M | Buy |
2,521,366
+1,369,863
| +119% | +$63.5M | 4.01% | 4 |
|
|
2022
Q1 | $78.1M | Hold |
1,151,503
| – | – | 1.83% | 8 |
|
|
2021
Q4 | $140M | Hold |
1,151,503
| – | – | 2.16% | 6 |
|
|
2021
Q3 | $162M | Hold |
1,151,503
| – | – | 1.7% | 6 |
|
|
2021
Q2 | $316M | Hold |
1,151,503
| – | – | 4.04% | 5 |
|
|
2021
Q1 | $246M | Buy |
1,151,503
+6,500
| +0.6% | +$1.8M | 3.95% | 5 |
|
|
2020
Q4 | $277M | Hold |
1,145,003
| – | – | 5.04% | 5 |
|
|
2020
Q3 | $121M | Hold |
1,145,003
| – | – | 3.33% | 6 |
|
|
2020
Q2 | $112M | Buy |
1,145,003
+233,333
| +26% | +$20.4M | 3.26% | 5 |
|
|
2020
Q1 | $68.6M | Hold |
911,670
| – | – | 3.21% | 6 |
|
|
2019
Q4 | $74M | Hold |
911,670
| – | – | 4.14% | 6 |
|
|
2019
Q3 | $111M | Hold |
911,670
| – | – | 6.08% | 5 |
|
|
2019
Q2 | $164M | Hold |
911,670
| – | – | 7.09% | 5 |
|
|
2019
Q1 | $146M | Hold |
911,670
| – | – | 5.52% | 5 |
|
|
2018
Q4 | $237M | Hold |
911,670
| – | – | 11.58% | 3 |
|
|
2018
Q3 | $222M | Hold |
911,670
| – | – | 14.68% | 2 |
|
|
2018
Q2 | $215M | Buy |
+911,670
| New | +$266M | 41.21% | 1 |
|
Other funds holding EVLO
Flagship Pioneering's EVLO Position: Q4 2023 in Review
Flagship Pioneering sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 7,932,624 shares — an estimated $31.1M sold.
Flagship Pioneering first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $316M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Flagship Pioneering reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Flagship Pioneering sold 7,932,624 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $31.1M.
- Flagship Pioneering first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Flagship Pioneering's Evelo Biosciences, Inc. Common Stock position peaked at $316M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Flagship Pioneering's 13F filing for Q4 2023, filed 14 Feb 2024.